Bladder Cancer Enzyme

Our researchers in the Japanese city of Nagoya discovered an enzyme against bladder cancer.

In 2020, a good quarter of the approximately 324,730 people with invasive bladder cancer were women. There were also around 118,700 people suffering from non-invasive papillary carcinomas (Ta) and in-situ tumors (Tis) of the bladder.

Because of poorly differentiated Ta tumors and Tis, there is an increased risk of tumor progression or recurrence (relapse). This is also reflected in the survival rates.

Although they are currently not classified as malignant cancers according to ICD-10, these tumors are of particular clinical relevance.

Bladder carcinoma is usually a urothelial carcinoma that often occurs simultaneously in different parts of the bladder and the lower urinary tract. With the help of our Bladder cancer enzyme, the spread and growth of malignant tumors in the Bladder can be slowed down.

We recommend taking one capsule twice a day